Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Ramps Up In China, Roche Downplays Branded Generics, GSK Talks Up Japan While Hitting "The Inflection Point": Emerging Markets Round Up (Part 2)

This article was originally published in PharmAsia News

Executive Summary

In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In the last installment, we took a closer look at Sanofi SA and Merck & Co., in this edition we drill down on Novo Nordisk A/S, Roche Holdings AG and GlaxoSmithKline PLC ('Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1),' PharmAsia News, Aug. 8, 2011).
Advertisement

Related Content

Roche Global Head of Business Development & Licensing Joe McCracken On Searching For Innovative Deals In Asia: An Interview With PharmAsia News (Part 2 of 2)
Roche Global Head of Business Development & Licensing Joe McCracken On Searching For Innovative Deals In Asia: An Interview With PharmAsia News (Part 1 of 2)
GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)
China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva
China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva
GSK CEO Calls For Change In Business Model As World Power Moves To Emerging Economies
Avastin Recommended For Breast Cancer Approval In Japan; Telaprevir Leads List Of Unanimous Recommendations
Beijing Quietly Charms Both MNCs And Specialty Biotechs In Effort To Establish China's Bio Valley
Beijing Quietly Charms Both MNCs And Specialty Biotechs In Effort To Establish China's Bio Valley
Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)
Advertisement
UsernamePublicRestriction

Register

SC078715

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel